All authors declare that they do not have any competing interests.
The role of bromocriptine in the treatment of patients with active rheumatoid arthritis
Version of Record online: 18 JAN 2013
© 2013 The Authors International Journal of Rheumatic Diseases © 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd
International Journal of Rheumatic Diseases
Volume 16, Issue 6, pages 662–666, December 2013
How to Cite
Salesi, M., Sadeghihaddadzavareh, S., Nasri, P., Namdarigharaghani, N., Farajzadegan, Z. and Hajalikhani, M. (2013), The role of bromocriptine in the treatment of patients with active rheumatoid arthritis. International Journal of Rheumatic Diseases, 16: 662–666. doi: 10.1111/1756-185x.12015
- Issue online: 31 DEC 2013
- Version of Record online: 18 JAN 2013
- Isfahan University of Medical Sciences
- disease activity index;
- rheumatoid arthritis
We decided to determine the effectiveness of oral bromocriptine in patients with active rheumatoid arthritis (RA) who are in methotrexate (MTX) therapy.
Patients receiving stable doses of MTX were randomized to one of two groups and received 3 months of double-blind bromocriptine (5 mg/day) or matching placebo. The moderate and major outcome measures were the proportion of patients with > 0.6 and > 1.2 improvement in RA based on the Disease Activity Score 28 (DAS28) at 3 months. Safety measures included adverse events and laboratory assessments.
On a background treatment of MTX, the percentage of patients with moderate and major DAS28 responses at 3 months in the bromocriptine group (73.8%/59.5%) was not significantly different from placebo (63.1%/31.6%). Side effects were typically mild and included mild nausea and sleep disturbance; we did not have any adverse events resulting in discontinuation of the study drug.
In patients with active RA receiving stable doses of MTX, bromocriptine showed non-significant improvement in efficiency outcomes compared to placebo.